MCID: ART008
MIFTS: 42

Arteriosclerosis Obliterans

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

MalaCards integrated aliases for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 38 56 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
KEGG 38 H01626
MeSH 45 D001162
SNOMED-CT 69 60625000
UMLS 74 C0003851

Summaries for Arteriosclerosis Obliterans

MalaCards based summary : Arteriosclerosis Obliterans is related to arteriosclerosis and intermittent claudication. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Cell adhesion molecules (CAMs). The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and bone marrow, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 77 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis 30.9 ADIPOQ HGF ICAM1 IL6 SELP VCAM1
2 intermittent claudication 30.5 IL6 SELP
3 peripheral vascular disease 30.4 IL6 SELP VCAM1
4 critical limb ischemia 30.3 HGF IL6
5 limb ischemia 30.3 HGF IL6
6 chronic venous insufficiency 30.1 ICAM1 SELP VCAM1
7 venous insufficiency 30.1 ICAM1 SELP VCAM1
8 myocardial infarction 30.1 ADIPOQ ICAM1 IL6 SELP
9 vascular disease 29.9 ADIPOQ IL6 SELP VCAM1
10 arteries, anomalies of 29.6 ADIPOQ ICAM1 IL6 SELP VCAM1
11 diabetes mellitus 10.4
12 buerger disease 10.4
13 heart disease 10.3
14 ischemia 10.3
15 obesity-hypoventilation syndrome 10.3 ADIPOQ IL6
16 aortic aneurysm 10.3
17 intermediate coronary syndrome 10.3 IL6 SELP
18 grange syndrome 10.3 SELP VCAM1
19 prediabetes syndrome 10.3 ADIPOQ IL6
20 lymphocytic vasculitis 10.2 ICAM1 VCAM1
21 apnea, obstructive sleep 10.2 ADIPOQ IL6
22 cortical thymoma 10.2 ICAM1 VCAM1
23 mooren's ulcer 10.2 ICAM1 VCAM1
24 shwartzman phenomenon 10.2 ICAM1 VCAM1
25 macular retinal edema 10.2 ICAM1 IL6
26 subendocardial myocardial infarction 10.2 ICAM1 VCAM1
27 post-thrombotic syndrome 10.2 ICAM1 IL6
28 actinic prurigo 10.2 ICAM1 VCAM1
29 ischemic heart disease 10.2
30 brachydactyly, type e2 10.2 ICAM1 VCAM1
31 hypersensitivity reaction type iii disease 10.2 ICAM1 IL6
32 rheumatoid vasculitis 10.2 ICAM1 VCAM1
33 limbal stem cell deficiency 10.2 ICAM1 VCAM1
34 localized scleroderma 10.2 IL6 VCAM1
35 leukostasis 10.2 ICAM1 VCAM1
36 coronary artery aneurysm 10.2 ADIPOQ VCAM1
37 plasmodium vivax malaria 10.2 ICAM1 IL6
38 nodular goiter 10.2 ICAM1 IL6
39 henoch-schoenlein purpura 10.2 ICAM1 VCAM1
40 diabetic macular edema 10.2 ICAM1 IL6
41 viral encephalitis 10.2 IL6 VCAM1
42 crescentic glomerulonephritis 10.2 ICAM1 VCAM1
43 extrinsic cardiomyopathy 10.2 ICAM1 IL6
44 coronary heart disease 1 10.1 ADIPOQ IL6 SELP
45 aortic aneurysm, familial abdominal, 1 10.1
46 systemic lupus erythematosus 10.1
47 lupus erythematosus 10.1
48 dengue disease 10.1 ICAM1 VCAM1
49 peripheral artery disease 10.1 IL6 SELP VCAM1
50 oral lichen planus 10.1 ICAM1 VCAM1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 ADIPOQ HGF ICAM1 IL6 MCAM SELP
2 hematopoietic system MP:0005397 9.17 ADIPOQ HGF ICAM1 IL6 MCAM SELP

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Probucol Approved, Investigational Phase 4 23288-49-5 4912
7
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9 Fibrinolytic Agents Phase 4
10 Peripheral Nervous System Agents Phase 4
11 Antipyretics Phase 4
12 Anti-Inflammatory Agents Phase 4
13 Analgesics, Non-Narcotic Phase 4
14 Platelet Aggregation Inhibitors Phase 4,Phase 2,Not Applicable
15 Bronchodilator Agents Phase 4
16 Respiratory System Agents Phase 4
17 Phosphodiesterase 3 Inhibitors Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19 Anti-Asthmatic Agents Phase 4
20 Phosphodiesterase Inhibitors Phase 4
21 Antirheumatic Agents Phase 4,Not Applicable
22 Analgesics Phase 4
23 Neuroprotective Agents Phase 4
24 Autonomic Agents Phase 4
25 Vasodilator Agents Phase 4,Phase 2
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Protective Agents Phase 4
28 Anesthetics Phase 4,Phase 1,Phase 2
29 Central Nervous System Depressants Phase 4
30 Anesthetics, General Phase 4
31 Anesthetics, Intravenous Phase 4
32 Anesthetics, Inhalation Phase 4
33 Analgesics, Opioid Phase 4
34 Hypnotics and Sedatives Phase 4
35 Narcotics Phase 4
36 Hypolipidemic Agents Phase 4
37 Lipid Regulating Agents Phase 4
38 Antimetabolites Phase 4
39 Antioxidants Phase 4
40 Anticholesteremic Agents Phase 4
41 Angiotensin Receptor Antagonists Phase 4
42 Giapreza Phase 4
43 Angiotensin-Converting Enzyme Inhibitors Phase 4
44 Angiotensinogen Phase 4
45 Antihypertensive Agents Phase 4
46 Angiotensin II Type 1 Receptor Blockers Phase 4
47 diuretics Phase 4
48 Sodium Chloride Symporter Inhibitors Phase 4
49 Natriuretic Agents Phase 4
50
Alprostadil Approved, Investigational Phase 2 745-65-3 5280723 149351

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4 cilostazol
2 Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
3 Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
4 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
5 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
6 A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans Unknown status NCT02877173 Phase 2 Alprostadil Liposomes for Injection;Alprostadil Injection
7 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Unknown status NCT02864654 Phase 1, Phase 2
8 Autologous Bone Marrow For Lower Extremity Ischemia Treating Completed NCT00753025 Phase 2
9 Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Recruiting NCT02501018 Phase 2 SOC
10 Recombinant SeV-hFGF2/dF Injection for PAOD Recruiting NCT03668353 Phase 1
11 TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Unknown status NCT00145262
12 Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy Unknown status NCT01984749 Not Applicable Febuxostat
13 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
14 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F) Completed NCT01518205 Not Applicable
15 Arterial Calcification in the Diabetes Active, not recruiting NCT02431234
16 A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan Active, not recruiting NCT01859897
17 Multi-center Study On the Treatment and Prognosis of Arteriosclerosis Obliterans With Different Caliber Balloon Not yet recruiting NCT03725683 Not Applicable

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

42
Heart, Bone, Bone Marrow, Smooth Muscle, Skin, Spinal Cord, Spleen

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 257)
# Title Authors Year
1
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. ( 31086587 )
2019
2
Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity. ( 31086577 )
2019
3
Outcomes in Patients with Critical Limb Ischemia due to Arteriosclerosis Obliterans Who Did Not Undergo Arterial Reconstruction. ( 30101855 )
2018
4
Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients. ( 29553861 )
2018
5
MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie. ( 29403548 )
2018
6
Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans. ( 28848136 )
2017
7
The Association between Polymorphism of CARD8 rs2043211 and Susceptibility to Arteriosclerosis Obliterans in Chinese Han Male Population. ( 28135700 )
2017
8
Baseline Characterization of Japanese Peripheral Arterial Disease Patients - Analysis of Surveillance of Cardiovascular Events in Antiplatelet-Treated Arteriosclerosis Obliterans Patients in Japan (SEASON). ( 26841805 )
2016
9
Emerging Novel Biomarkers for Arteriosclerosis Obliterans. ( 26632166 )
2016
10
Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. ( 26370316 )
2016
11
A Rare Complication of Spinal Cord Ischemia Following Endovascular Aneurysm Repair of an Infrarenal Abdominal Aortic Aneurysm with Arteriosclerosis Obliterans: Report of a Case. ( 27738476 )
2016
12
[Logistic Regression Analysis of Depression in Arteriosclerosis Obliterans Patients and Its Risk Factors]. ( 26564507 )
2015
13
Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. ( 26159387 )
2015
14
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. ( 25959199 )
2015
15
MicroRNA-133a in the Development of Arteriosclerosis Obliterans. ( 25740337 )
2015
16
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. ( 25445891 )
2015
17
MiR-142-3p attenuates the migration of CD4⁺ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. ( 24743945 )
2014
18
Relationship between arteriosclerosis obliterans and the ratio of serum eicosapentaenoic acid to arachidonic acid. ( 23364231 )
2014
19
Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. ( 23749750 )
2013
20
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( 23364237 )
2013
21
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. ( 22259111 )
2012
22
A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. ( 23097651 )
2012
23
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. ( 23065872 )
2012
24
MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. ( 21817107 )
2011
25
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). ( 20966606 )
2010
26
Characteristics of revascularization treatment for arteriosclerosis obliterans in patients with and without hemodialysis. ( 20938099 )
2010
27
Current status of the medical expenses for the treatment of arteriosclerosis obliterans in Japan. ( 20357751 )
2010
28
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. ( 20357749 )
2010
29
[Evaluation of proinflammatory cytokines in chronic lower limb ischaemia diabetic macroangiopathy and arteriosclerosis obliterans]. ( 20120706 )
2009
30
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. ( 19225945 )
2009
31
Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans. ( 18175063 )
2008
32
Detecting vulnerable plaque of arteriosclerosis obliterans by multidetector-row computed tomography--comparing with VH (virtual histology)-intravascular ultrasound. ( 17512620 )
2008
33
Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). ( 18724029 )
2008
34
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. ( 18375400 )
2008
35
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. ( 18270875 )
2008
36
Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. ( 18064333 )
2007
37
Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. ( 17652880 )
2007
38
Intractable wounds caused by arteriosclerosis obliterans with end-stage renal disease treated by aggressive debridement and epidermal grafting. ( 17637445 )
2007
39
Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. ( 17610290 )
2007
40
Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. ( 17186986 )
2007
41
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. ( 17126824 )
2007
42
[Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans]. ( 17087295 )
2006
43
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. ( 17249520 )
2006
44
Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. ( 16865304 )
2006
45
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. ( 16763534 )
2006
46
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. ( 15877296 )
2005
47
Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. ( 15488869 )
2004
48
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. ( 15372302 )
2004
49
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. ( 15224807 )
2004
50
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. ( 15203718 )
2004

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 MCAM SELP VCAM1
2 extracellular space GO:0005615 9.17 ADIPOQ HGF ICAM1 IL6 MCAM SELP

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.83 ICAM1 MCAM SELP VCAM1
2 response to hypoxia GO:0001666 9.69 ADIPOQ ICAM1 VCAM1
3 response to lipopolysaccharide GO:0032496 9.63 ICAM1 SELP VCAM1
4 cytokine-mediated signaling pathway GO:0019221 9.62 HGF ICAM1 IL6 VCAM1
5 negative regulation of fat cell differentiation GO:0045599 9.58 ADIPOQ IL6
6 response to ionizing radiation GO:0010212 9.57 ICAM1 VCAM1
7 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.56 ADIPOQ CARD8
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.55 ADIPOQ TPM1
9 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.54 HGF ICAM1
10 response to ethanol GO:0045471 9.54 ADIPOQ ICAM1 VCAM1
11 calcium-mediated signaling using intracellular calcium source GO:0035584 9.49 SELP VCAM1
12 negative regulation of tumor necrosis factor-mediated signaling pathway GO:0010804 9.48 ADIPOQ CARD8
13 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.43 ADIPOQ TPM1
14 leukocyte tethering or rolling GO:0050901 9.4 SELP VCAM1
15 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.33 ICAM1 SELP VCAM1
16 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
17 leukocyte cell-cell adhesion GO:0007159 9.13 ICAM1 SELP VCAM1
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 8.92 ADIPOQ HGF ICAM1 IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sialic acid binding GO:0033691 8.62 ADIPOQ SELP

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....